REGN FY 2009 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$79B

FY 2009 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$379M+59.1% YoY

Gross Profit

$363M95.8% margin

Operating Income

-$74M-19.5% margin

Net Income

-$68M-17.9% margin

EPS (Diluted)

$-0.85

Cash Flow

Operating Cash Flow

-$72M

Free Cash Flow

-$170M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$741M

Total Liabilities

$344M

Stockholders' Equity

$397M

Cash & Equivalents

$207M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$379M	$238M	+59.1%
Gross Profit	$363M	$226M	+60.6%
Operating Income	-$74M	-$90M	+17.5%
Net Income	-$68M	-$83M	+18.0%